Finasteride: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) parser-claude batch MedTemplate pre-fill, Top 300 #91 |
MDElliottMD (talk | contribs) home-claude category backfill (parser-claude gap closure) |
||
| Line 21: | Line 21: | ||
== References == | == References == | ||
<references /> | <references /> | ||
[[Category:5-alpha-reductase inhibitors]] | |||
[[Category:BPH treatments]] | |||
[[Category:Androgen modulators]] | |||
Latest revision as of 10:43, 23 May 2026
Finasteride
Proscar (5 mg, BPH), Propecia (1 mg, alopecia)
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Benign prostatic hyperplasia0, Androgenetic alopecia (male pattern hair loss)0, Off-label: hirsutism, feminizing GAHT adjunct0
Pharmacy
Starting dose
5 mg PO daily for BPH; 1 mg PO daily for androgenetic alopecia
Preparations
1 mg, 5 mg tablets
US FDA Max
5 mg/d
Pharmacology
Routes
Oral
Onset
BPH symptom improvement at 3-6 months; prostate volume reduction over 6-12 months; hair regrowth at 6-12 months
Duration
24 hours
Half-life
~5-6 hours in young men, ~8 hours in elderly[1]
Bioavailability
~63% (oral)[1]
Pregnancy
Pregnant individuals should not handle crushed/broken tablets (skin absorption risk); can cause hypospadias in male fetus. Not used in pregnancy.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Finasteride is a selective inhibitor of type II 5α-reductase, the dominant prostatic isoform converting testosterone to dihydrotestosterone (DHT); DHT lowering ~70% shrinks androgen-dependent prostatic tissue and the dermal papilla of androgen-sensitive hair follicles.0 Dutasteride inhibits both type I and II isoforms with deeper DHT suppression but a similar clinical effect. Post-finasteride syndrome (persistent sexual and mood effects after discontinuation) is a controversial but recognized clinical concern that the FDA acknowledged in 2012 labeling[1].
References
- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Proscar (finasteride), Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020180s044lbl.pdf